DE60100858T2 - Prozess zur herstellung der kristallinen form i von cabergolin - Google Patents

Prozess zur herstellung der kristallinen form i von cabergolin Download PDF

Info

Publication number
DE60100858T2
DE60100858T2 DE60100858T DE60100858T DE60100858T2 DE 60100858 T2 DE60100858 T2 DE 60100858T2 DE 60100858 T DE60100858 T DE 60100858T DE 60100858 T DE60100858 T DE 60100858T DE 60100858 T2 DE60100858 T2 DE 60100858T2
Authority
DE
Germany
Prior art keywords
cabergoline
toluene
solvate
diethyl ether
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60100858T
Other languages
German (de)
English (en)
Other versions
DE60100858D1 (de
Inventor
Attilio Tomasi
Stefania Magenes
Mario Ungari
Giuliano Ramella
Gianfranco Pallanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60100858(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of DE60100858D1 publication Critical patent/DE60100858D1/de
Application granted granted Critical
Publication of DE60100858T2 publication Critical patent/DE60100858T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60100858T 2000-03-24 2001-03-19 Prozess zur herstellung der kristallinen form i von cabergolin Expired - Fee Related DE60100858T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007308 2000-03-24
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
DE60100858D1 DE60100858D1 (de) 2003-10-30
DE60100858T2 true DE60100858T2 (de) 2004-07-29

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60100858T Expired - Fee Related DE60100858T2 (de) 2000-03-24 2001-03-19 Prozess zur herstellung der kristallinen form i von cabergolin

Country Status (31)

Country Link
US (2) US6727363B2 (cg-RX-API-DMAC7.html)
EP (1) EP1272489B1 (cg-RX-API-DMAC7.html)
JP (1) JP4184666B2 (cg-RX-API-DMAC7.html)
KR (1) KR100827558B1 (cg-RX-API-DMAC7.html)
CN (1) CN1188412C (cg-RX-API-DMAC7.html)
AR (1) AR032449A1 (cg-RX-API-DMAC7.html)
AT (1) ATE250601T1 (cg-RX-API-DMAC7.html)
AU (2) AU780747B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109507A (cg-RX-API-DMAC7.html)
CA (1) CA2402836A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20023176A3 (cg-RX-API-DMAC7.html)
DE (1) DE60100858T2 (cg-RX-API-DMAC7.html)
DK (1) DK1272489T3 (cg-RX-API-DMAC7.html)
EA (1) EA005928B1 (cg-RX-API-DMAC7.html)
EE (1) EE05088B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208602T3 (cg-RX-API-DMAC7.html)
GB (1) GB0007308D0 (cg-RX-API-DMAC7.html)
HK (1) HK1052348B (cg-RX-API-DMAC7.html)
HU (1) HUP0300591A3 (cg-RX-API-DMAC7.html)
IL (2) IL150985A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02009283A (cg-RX-API-DMAC7.html)
MY (1) MY134189A (cg-RX-API-DMAC7.html)
NO (1) NO20024321L (cg-RX-API-DMAC7.html)
NZ (1) NZ521316A (cg-RX-API-DMAC7.html)
PE (1) PE20011140A1 (cg-RX-API-DMAC7.html)
PL (1) PL358253A1 (cg-RX-API-DMAC7.html)
PT (1) PT1272489E (cg-RX-API-DMAC7.html)
SI (1) SI1272489T1 (cg-RX-API-DMAC7.html)
SK (1) SK13582002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001070740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200206045B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
RS81804A (sr) * 2002-03-15 2006-10-27 Pharmacia Corporation Postupak za dobijanje kristalnog oblika kabergolina
WO2003078392A2 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
AU2004238833A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
JPH08502759A (ja) 1993-08-18 1996-03-26 アルコン ラボラトリーズ,インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
PL343593A1 (en) 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline

Also Published As

Publication number Publication date
US20040092744A1 (en) 2004-05-13
AU2005203071A1 (en) 2005-08-11
DK1272489T3 (da) 2003-12-15
NZ521316A (en) 2004-05-28
MXPA02009283A (es) 2003-03-12
SK13582002A3 (sk) 2003-04-01
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
AU6211001A (en) 2001-10-03
EA200201016A1 (ru) 2003-02-27
EA005928B1 (ru) 2005-08-25
MY134189A (en) 2007-11-30
HK1052348B (zh) 2005-09-16
ZA200206045B (en) 2003-07-29
AR032449A1 (es) 2003-11-12
GB0007308D0 (en) 2000-05-17
IL150985A0 (en) 2003-02-12
PT1272489E (pt) 2004-02-27
JP4184666B2 (ja) 2008-11-19
KR100827558B1 (ko) 2008-05-07
EE05088B1 (et) 2008-10-15
US6953854B2 (en) 2005-10-11
NO20024321D0 (no) 2002-09-10
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DE60100858D1 (de) 2003-10-30
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
HK1052348A1 (en) 2003-09-11
PE20011140A1 (es) 2001-11-01
WO2001070740A1 (en) 2001-09-27
ATE250601T1 (de) 2003-10-15
CN1188412C (zh) 2005-02-09
PL358253A1 (en) 2004-08-09
HUP0300591A3 (en) 2009-01-28
NO20024321L (no) 2002-09-10
EE200200545A (et) 2004-04-15
US6727363B2 (en) 2004-04-27
AU780747B2 (en) 2005-04-14
EP1272489A1 (en) 2003-01-08
US20030149067A1 (en) 2003-08-07
EP1272489B1 (en) 2003-09-24
HUP0300591A2 (hu) 2003-07-28
JP2003528100A (ja) 2003-09-24
SI1272489T1 (en) 2004-02-29
IL150985A (en) 2007-03-08
KR20020081587A (ko) 2002-10-28

Similar Documents

Publication Publication Date Title
DE69300532T2 (de) Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE69716062T2 (de) Benzofuran-derivate und deren verwendung
DE60225307T2 (de) Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
DE69229339T2 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DE2411382A1 (de) Neue 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung
EP2464648B1 (de) Kristalline Verbindung von 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorphenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluormethyl)-1,2,4-triazolo[4,3-a]pyrazin
AU2005203071B2 (en) Process for preparing crystalline form I of cabergoline
DE60107074T2 (de) Kristallin form ii von cabergolin
DE68904342T2 (de) Cyclische amide.
DE3887598T2 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron.
DE69406607T2 (de) Komplexe von bicyclischen beta-Lactamen und Parabenen
DE60220024T2 (de) Pyrimidinnukleosidderivatkristall
DE69917282T2 (de) Verfahren zur herstellung von zofenopril-calciumsalz
DE112020001275T5 (de) Bulleyaconitin d kristall, verfahren zu seiner herstellung und seine verwendung
EP2407467A1 (de) Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
EP0155903A1 (de) Indolophenanthridine, ihre Herstellung und Verwendung
DE60205504T2 (de) Zitronensäure salz von einer therapeutischen verbindung und deren pharmazeutischen zusammensetzungen
DE68905363T2 (de) Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
DE3780438T2 (de) N-substituierte cyclische amine, ihre herstellung sowie pharmazeutische zusammensetzungen die sie enthalten.
DE3327705A1 (de) Mutterkornalkaloide, ihre herstellung und verwendung
EP4208453B1 (de) Verfahren zur herstellung eines tetrazol-substituierten anthranilsäurediamid-derivates
DE60104822T2 (de) Pseudopolymorph von (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-on hydrochlorid
DE2509797C2 (de) Phthalimidine, deren physiologisch verträgliche Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE60217168T2 (de) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dion-benzolsulfonat; prozess zu seiner herstellung; polymorphe i, ii und iii davon; und seine verwendung als pharmazeutischer wirkstoff
AT217465B (de) Verfahren zur Herstellung neuer Ester der Indol-Reihe

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA ITALIA S.P.A., MAILAND/MILANO, IT

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee